MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, net
$93,637,829
Net cash provided
by/(used in) financing...
$93,564,808
Canceled cashflow
$73,021
Net decrease in cash
and cash...
-$360,486
Canceled cashflow
$93,564,808
Sale of short-term
investments
$35,690,270
Stock-based compensation
$13,905,181
Stock appreciation
rights compensation
$1,056,464
Issuance of restricted
common stock
$905,226
Realized (gain) loss on
short-term investments
-$79,207
Payment of atm fees
$73,021
Net cash (used
in)/provided by investing...
-$48,138,306
Canceled cashflow
$35,690,270
Net cash used in
operating activities
-$45,786,988
Canceled cashflow
$15,946,078
Purchase of short-term
investments
$83,828,576
Net loss
-$57,385,163
Accounts payable
-$2,561,619
Accrued expenses
-$1,299,244
Unrealized gain on
short-term investments
$398,255
Prepaid expenses and
other assets
$88,785
Back
Back
Cash Flow
source: myfinsight.com
RELMADA THERAPEUTICS, INC. (RLMD)
RELMADA THERAPEUTICS, INC. (RLMD)